Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues

• Published in: Experimental and therapeutic medicine Vol. 21; no. 3; p. 216
• Main Authors: Li, Yue, Pan, Calvin Q, Ji, Shibo, Yan, Gaiqin, Cheng, Jun, Liu, Shunai, Xing, Huichun
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications UK Ltd 01.03.2021; D.A. Spandidos
• Subjects: Antigens; Antiviral drugs; Clinical outcomes; Cytokines; Deoxyribonucleic acid; Disease; DNA; Hepatitis B; Immunoassay; Laboratories; Liver cancer; Lymphocytes; Serology; Beijing China; China; outcome predictors; suboptimal response; hepatitis B virus; IL-21; antiviral therapy
• ISSN: 1792-0981; 1792-1015
• DOI: 10.3892/etm.2021.9648

To investigate whether IL-21 levels predict treatment outcomes of salvage therapy among patients with suboptimal response (SOR) to nucleos(t)ide analogues (NAs), serum IL-21 levels were measured in a prospective cohort of hepatitis B e antigen (HBeAg)-positive patients with SOR to antiviral therapy. The patients switched therapy to entecavir (ETV) with or without adefovir (ADV) for 104 weeks. IL-21 levels at treatment week 12 in patients who achieved HBeAg loss with undetectable levels of hepatitis B virus (HBV)-DNA at week 104 were the primary endpoint and the results were compared with those of corresponding patients without such an endpoint. Furthermore, IL-21 levels at treatment week 12 in patients who achieved an HBeAg-level decline at week 104 were assessed as the secondary endpoint. Among 24 enrolled patients with SOR to ADV (n=21), telbivudine (n=2) or ETV (n=1), the median (10-90th percentile) levels of HBeAg, HBV-DNA and ALT at baseline were 2.7 (0.2-3.1) log S/CO, 5.2 (3.5-7.5) log IU/ml and 0.9 (0.5-3.1) upper limit of normal, respectively. Comparison of the patients with and without HBeAg loss at week 104 indicated that their mean IL-21 levels did not significantly differ at week 12 (63.0±14.4 vs. 55.9±10.5 pg/ml; P=0.26). In the secondary endpoint analyses of patients with and without HBeAg level decline, the elevated levels of IL-21 at the first 12 weeks were significantly higher in the decline group (15.6±8.3 vs. 3.1±13.2 pg/ml; P=0.03). Following adjustment for confounding factors, the elevated levels of IL-21 from baseline to week 12 independently predicted an HBeAg level decline at week 104 (odds ratio=1.137, R =0.23; P=0.047). In conclusion, the serum IL-21 levels at the first 12 weeks during the salvage therapy independently predicted HBeAg level decline at treatment week 104 in patients with SOR to NAs (ClinicalTrials.gov identifier: NCT01829685; date of registration, April 2013).